| Literature DB >> 31751357 |
Dong Wook Jekarl1,2, Seungok Lee2,3, Jung Hyun Kwon4, Soon Woo Nam4, Myungshin Kim1,2, Yonggoo Kim1,2, Jeong Won Jang5.
Abstract
Treating hepatocellular carcinoma with transarterial chemoembolization (TACE) induces both local inflammation in the tumor microenvironment as well as systemic inflammation. We analyzed serum cytokine response to TACE to evaluate this. Serum samples obtained from 203 HCC patients treated with TACE were analyzed for inflammatory cytokines including interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-13, IL-17, IL-22, TNF-α, IFN-γ, and C-reactive protein (CRP) levels. Cytokine concentrations were measured at day 0 (D0, baseline, n = 203), day3 (D3, n = 156), day7 (D7, n = 147), and day 60 (D60, n = 115) after TACE. Network analysis of the cytokines was performed to understand their interactive relationship. After TACE, IL-1β, -6,-9, -12, and -22 increased by D60. IL-2, -5, -10, -17A and INF-γ decreased by D60, and IL-4, -13 and TNF-α revealed stable concentration. D0 network revealed that IL-2, -4, -5, and -10 formed a module. D3 network had the highest clustering coefficient and average degree that revealed similar pattern as CRP. D7 network revealed that IL-6, -9 and CRP were isolated from the network. D60 network had the lower network heterogeneity and lower clustering coefficient, network diameter, shortest path and characteristic path length. Degree correlation revealed that assortative network turned to disassortative network by D60 indicating that the network gained scale free feature. D60 cytokine network retained inflammatory function and these parameters indicated that the systemic inflammation induced by TACE appeared to be attenuated by D60. IL-9 at D3 and D7 seemed to be related to anti-tumor effect and IL-6 at D7 and D60, and IL-22 at D60 was related to regenerative but not pro- or anti- inflammatory function. Median survival month of patient group with high and low values of cytokine with P-values were as follows: D0 CRP, 9.5 and 54.2 months (P<0.0001); D0 IL-2, 39.9 and 56.1 months (P = 0.0084); D3 CRP, 31.3 and 55.1 months (P = 0.0056); D7 CRP, 28.7 and 50.7 months (P = 0.0065), respectively. TACE is associated with systemic inflammation which appears to peak at Day 3 and resolve by D60. Among the tested cytokines, IL-6 and IL-22 appear to play a regenerative role.Entities:
Year: 2019 PMID: 31751357 PMCID: PMC6874208 DOI: 10.1371/journal.pone.0224318
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline patient characteristics.
| Patient (n = 203) | |
|---|---|
| Age (year) | 58 (40–84) |
| Sex, Male / Female | 164 / 39 |
| Etiology, HBV / HCV / Alcohol / Others | 142 / 17 / 22 / 22 |
| Ascite, None / Present | 172 / 31 |
| Portal hypertension, None / Present | 155 / 48 |
| ECOG, 0 / 1 / 2 / 3 | 115 / 49 / 27 / 4 |
| Child Pugh Class, A / B / C | 141 / 49 / 5 |
| Tumor Maximum Size (cm) | 5.7 (0.8–28) |
| Tumor number, single / multiple | 102 / 101 |
| Metastasis, None / present | 169 / 34 |
| Treatment | |
| TAC / +PEI / +Radiation / Sorafenib / Others | 127 / 3 / 16 / 5 / 52 |
| Laboratory data, median (range) | |
| Platelet (x109/L) | 131 (0.95–502) |
| Prothrombin time (INR) | 1.22 (0.98–2.46) |
| Bilirubin (mg/dL) | 1.2 (0.3–9.7) |
| AST (U/L) | 51.5 (11–522) |
| ALT (U/L) | 36 (11–392) |
| Albumin (d/dL) | 3.6 (0.8–5.1) |
| Creatinine (mg/dL) | 0.7 (0.4–1.3) |
| Sodium (mmol/L) | 138 (125–144) |
| AFP (ng/mL) | 57.6 (1.3–3,000) |
| PIVKA-II (mAU) | 193 (10–75000) |
HBV, hepatitis B virus; HCV, hepatitis C virus; TAC, transarterial chemotherapy; PEI, percutaneous ethanol infection; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist II.
aThe continuous variables are presentedas median (range).
bFor ECOG (Eastern Cooperative Oncology Group) and Child Pugh classification, 8 patients had no data.
Measured cytokine levels for patients before transarterial chemotherapy (D0) and at 3 days (D3), 7 days (D7), and 60 days (D60) post-transarterial chemotherapy.
| D0 (n = 203) | D3 (n = 156) | D7 (n = 147) | D60 (n = 115) | |||||
|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| IL-12 | 11.46 | 53.95 | 8.95 | 46.52 | 10.86 | 46.71 | 25.48 | 130.98 |
| IFN-γ | 34.02 | 165.42 | 24.05 | 142.76 | 30.33 | 171.63 | 21.16 | 99.06 |
| IL-17α | 31.26 | 134.65 | 21.81 | 82.72 | 23.73 | 106.26 | 22.48 | 102.59 |
| IL-2 | 98.68 | 774.16 | 44.45 | 122.68 | 43.53 | 133.72 | 40.15 | 122.75 |
| IL-10 | 32.01 | 334.54 | 7.34 | 40.74 | 7.84 | 46.82 | 8.719 | 35.45 |
| IL-9 | 12.43 | 83.41 | 7.71 | 35.66 | 7.79 | 31.23 | 20.85 | 77.88 |
| IL-22 | 201.09 | 333.01 | 149.47 | 255.87 | 154.84 | 259.79 | 280.74 | 668.21 |
| IL-6 | 4.77 | 16.22 | 14.44 | 40.36 | 9.32 | 24.56 | 56.16 | 495.97 |
| IL-13 | 34.62 | 52.88 | 37.33 | 58.71 | 35.78 | 57.49 | 37.45 | 42.83 |
| IL-4 | 40.31 | 123.77 | 34.95 | 89.99 | 33.75 | 100.49 | 39.24 | 97.95 |
| IL-5 | 95.61 | 1212.58 | 9.56 | 67.06 | 11.08 | 86.32 | 7.51 | 76.49 |
| IL-1β | 19.70 | 91.06 | 21.21 | 88.35 | 24.47 | 110.45 | 26.62 | 91.76 |
| TNF-α | 26.11 | 138.56 | 29.84 | 133.78 | 29.22 | 175.53 | 24.67 | 117.66 |
| CRP | 19.45 | 37.14 | 38.67 | 41.21 | 32.62 | 44.19 | 26.93 | 43.72 |
IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; CRP, C-reactive protein; SD, standard deviation.
aStatistical analysis was performed using a Kruskal-Wallis test for analysis of variance among D0, D3,D7and D60 and only CRP revealed statistical significance. Units for cytokines are as follows: CRP, mg/L; others, pg/mL.
Fig 1Cytokine concentrations at D0, D3, D7 and D60.
Fig 2Cytokine Network of hepatocellular carcinoma after TACE.
Network analysis results at (A) D0, (B) D3, (C) D7 and (D) D60 after transarterial chemotherapy are presented.
Network topological parameters of D0, D3, D7, and D60 after transarterial chemotherapy.
| D0 | D3 | D7 | D60 | |
|---|---|---|---|---|
| Clustering Coefficient, < | 0.797 | 0.962 | 0.831 | 0.813 |
| Network density | 0.473 | 0.731 | 0.705 | 0.742 |
| Network heterogeneity | 0.398 | 0.338 | 0.378 | 0.307 |
| Connected components | 1 | 1 | 2 | 1 |
| Network diameter | 4 | 2 | 2 | 2 |
| Network centralization | 0.346 | 0.318 | 0.152 | 0.309 |
| Shortest path | 182 | 156 | 112 | 132 |
| Characteristic path length | 1.681 | 1.269 | 1.018 | 1.258 |
| Average degree, < | 6.143 | 8.769 | 8.462 | 8.167 |
| Number of nodes, | 14 | 13 | 13 | 12 |
| Degree correlation, μ | 0.281 | 0.209 | 1 | -0.315 |
| Modularity, | 0.177 | 0.038 | 0.036 | -0.091 |
Fig 3Patient outcome by cytokine status.
Overall survival of patient group by high and low concentration of cytokines after transarterial chemotherapy is presented. (A) CRP and IL-2 at D0, (B) CRP and IL-6 at D3,(C) CRP at D7 and (D) CRP at D60.